Phase 2 Study of Avapritinib in Patients with CKIT or PDGFRA Mutation-Positive Malignant Solid Tumors

Disease:

Anatomic Stage IV Breast Cancer AJCC V8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC V8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC V8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC V8, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma, Locally Advanced Primary Malignant Central Nervous System Neoplasm, Locally Advanced Sarcoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Primary Malignant Central Nervous System Neoplasm, Metastatic Sarcoma, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC V8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC V8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC V8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC V8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC V8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC V8, Prognostic Stage IIIC Breast Cancer AJCC V8, Prognostic Stage IV Breast Cancer AJCC V8, Stage IIIC Colorectal Cancer AJCC V8, Stage IIIC Lung Cancer AJCC V8, Stage IV Colorectal Cancer AJCC V8, Stage IV Lung Cancer AJCC V8, Stage IVA Colorectal Cancer AJCC V8, Stage IVA Lung Cancer AJCC V8, Stage IVB Colorectal Cancer AJCC V8, Stage IVB Lung Cancer AJCC V8, Stage IVC Colorectal Cancer AJCC V8

Study phase:

Phase II

Physician name:

Jordi Rodon Ahnert

Department:

Investigational Cancer Therapeutics

For general questions about clinical trials:

1-877-632-6789